Exp Hematol. 2022 Aug 4:S0301-472X(22)00581-1. doi: 10.1016/j.exphem.2022.07.303. Online ahead of print.
ABSTRACT
The combination of pomalidomide with dexamethasone is approved for the treatment of relapsed/refractory multiple myeloma (RRMM). This phase 2, multicenter, open-label, non-randomized study investigated pomalidomide as a replacement for lenalidomide for 45 patients with RRMM refractory to a lenalidomide-containing combination regimen containing steroids and ≥1 other anti-myeloma agent administered using the same schedule(s), dose(s), and drug combination. Pomalidomide was administered on days 1-21 of a 28-day cycle for ≤8 cycles at doses of 2, 3 or 4 mg. Overall response rates (ORR) and clinical benefit rates (CBR) were 33% and 44%, respectively and were higher among those who received 4 mg pomalidomide (ORR 41% and CBR 50%). Median progression-free survival and overall survival were 8 and 16 months, respectively. Adverse events were consistent with the established safety profiles for the individual agents and the replacement of lenalidomide with pomalidomide did not appear to result in greater toxicity. Overall, this study indicates that pomalidomide can be an effective and safe replacement for lenalidomide among patients with RRMM refractory to the latter immunomodulatory agent without requiring additional changes to the combination regimen. #NCT02188368.
PMID:35934183 | DOI:10.1016/j.exphem.2022.07.303